Santen Pharmaceutical Co Ltd (SNPHY)
Institutional ownership reported to the SEC as of Q2 2026, across 29 quarters.
1
Reporting holders
$403
Reported value
0.0%
Held as options
+0
Holder change
Options share is the part of reported value carried in derivative lines rather than shares. A high figure means institutions are expressing a view on this security without owning much of it.
Holders
| Filer | Value | Shares | Their book | Held | Change |
|---|---|---|---|---|---|
| RHUMBLINE ADVISERS | $403 | 30 | 0.00% | 13q | HELD |
Quarter by quarter
Coverage begins with the quarter ending 2018-12-31. Earlier filings exist only as occasional late amendments, too sparse to describe a market, so they are not shown.
| Quarter | Holders | Value | Shares | New | Added | Trimmed | Options |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1 | $403 | 30 | 0 | 0 | 0 | 0.0% |
| Q1 2026 | 1 | $333 | 30 | 0 | 0 | 1 | 0.0% |
| Q4 2025 | 2 | $15.3K | 1,483 | 0 | 0 | 0 | 0.0% |
| Q3 2025 | 2 | $16.7K | 1,483 | 0 | 1 | 0 | 0.0% |
| Q2 2025 | 2 | $3.7K | 316 | 0 | 1 | 0 | 0.0% |
| Q1 2025 | 2 | $2.5K | 260 | 0 | 0 | 0 | 0.0% |
| Q4 2024 | 3 | $2.9K | 286 | 1 | 0 | 0 | 0.0% |
| Q3 2024 | 2 | $678 | 56 | 0 | 0 | 0 | 0.0% |
| Q2 2024 | 2 | $572 | 56 | 0 | 0 | 0 | 0.0% |
| Q1 2024 | 2 | $547 | 56 | 1 | 0 | 0 | 0.0% |
| Q4 2023 | 1 | $295 | 30 | 0 | 0 | 0 | 0.0% |
| Q3 2023 | 1 | $273 | 30 | 0 | 0 | 0 | 0.0% |
| Q2 2023 | 1 | $253 | 30 | 1 | 0 | 0 | 0.0% |
| Q3 2022 | 1 | $1.0K | 199 | 0 | 0 | 0 | 0.0% |
| Q2 2022 | 3 | $19.0K | 2,363 | 1 | 0 | 1 | 0.0% |
| Q1 2022 | 2 | $28.0K | 2,762 | 1 | 1 | 0 | 0.0% |
| Q4 2021 | 1 | $29.0K | 2,409 | 0 | 1 | 0 | 0.0% |
| Q3 2021 | 3 | $24.0K | 1,672 | 0 | 1 | 1 | 0.0% |
| Q2 2021 | 4 | $29.0K | 2,081 | 0 | 1 | 1 | 0.0% |
| Q1 2021 | 5 | $19.8M | 1,424,592 | 1 | 0 | 2 | 0.0% |
| Q4 2020 | 4 | $25.7M | 1,578,073 | 1 | 2 | 0 | 0.0% |
| Q3 2020 | 3 | $31.9M | 1,551,905 | 0 | 0 | 1 | 0.0% |
| Q2 2020 | 3 | $29.0M | 1,574,721 | 0 | 1 | 1 | 0.0% |
| Q1 2020 | 5 | $22.9M | 1,346,882 | 1 | 2 | 0 | 0.0% |
| Q4 2019 | 5 | $25.4M | 1,331,753 | 0 | 3 | 1 | 0.0% |
| Q3 2019 | 5 | $22.0M | 1,267,823 | 0 | 2 | 3 | 0.0% |
| Q2 2019 | 6 | $19.7M | 1,194,356 | 1 | 3 | 2 | 0.0% |
| Q1 2019 | 7 | $13.8M | 927,986 | 2 | 1 | 3 | 0.0% |
| Q4 2018 | 5 | $14.9M | 1,042,130 | 0 | 0 | 0 | 0.0% |